Toca­gen li­cens­es im­munother­a­py to Apol­lo­Bio for $16M up­front; WuXi AppTec un­veils ex­pand­ed lab test­ing site in New Jer­sey

→ San Diego-based Toca­gen $TO­CA has inked a li­cens­ing deal with Apol­lo­Bio, giv­ing an af­fil­i­ate of the Bei­jing-based com­pa­ny an ex­clu­sive li­cense to de­vel­op and com­mer­cial­ize its can­cer-se­lec­tive im­munother­a­py. Toca­gen’s treat­ment, called To­ca 511 & To­ca FC, is cur­rent­ly in a Phase III tri­al in pa­tients with cer­tain brain tu­mors. The deal gives Apol­lo­Bio rights in greater Chi­na, in­clud­ing main­land, Hong Kong, Macao, and Tai­wan. Toca­gen will get a $16 mil­lion up­front pay­ment, along with $4 mil­lion in “near-term” mile­stone pay­ments. The com­pa­ny’s al­so el­i­gi­ble for ad­di­tion­al fu­ture pay­ments to­tal­ing $111 mil­lion, Toca­gen said in a state­ment. “As an in­no­v­a­tive bio­phar­ma­ceu­ti­cal com­pa­ny in Chi­na, Apol­lo­Bio is well po­si­tioned to lever­age Chi­na’s re­cent reg­u­la­to­ry changes sup­port­ing the de­vel­op­ment of new med­i­cines,” said Mar­ty Du­vall, CEO of Toca­gen, in a state­ment. “Apol­lo­Bio brings valu­able re­gion­al ex­per­tise in prod­uct de­vel­op­ment, reg­u­la­tion and health­care ac­cess, po­si­tion­ing our lead prod­uct to ad­vance to­wards pa­tients in the greater Chi­na re­gion as quick­ly and ef­fi­cient­ly as pos­si­ble.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.